Deciphering COVID-19 host transcriptomic complexity and variations for therapeutic discovery against new variants
Jing Xing, Rama Shankar, Meehyun Ko, Keke Zhang, Sulin Zhang, Aleksandra Drelich, Shreya Paithankar, Eugene Chekalin, Mei‐Sze Chua, Surender Rajasekaran, Chien‐Te K. Tseng, Mingyue Zheng, Seungtaek Kim, Bin Chen
Abstract
against SARS-CoV-2 and its five variants. IMD-0354 stimulated type I interferon antiviral response, inhibited viral entry, and down-regulated hijacked proteins. This study demonstrates that the conserved coronavirus signatures and the transcriptomic reversal approach that leverages polypharmacological effects could guide new variant therapeutic discovery.
Topics & Concepts
TranscriptomeDrug discoveryCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Host (biology)Computational biologyBiology2019-20 coronavirus outbreakGeneVirologyGene expressionBioinformaticsGeneticsMedicineDiseaseInfectious disease (medical specialty)OutbreakPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studiesinterferon and immune responses